logo
An Archaeologist Sailed the Seas Using Only Viking Tech. Here's What He Learned

An Archaeologist Sailed the Seas Using Only Viking Tech. Here's What He Learned

Gizmodo25-05-2025

Vikings were formidable Scandinavian warriors and sailors who, from around 800 to 1050 CE, raided, traded, and settled throughout northern Europe, Iceland, Greenland, and even as far as North America. Most of what scholars know about Viking maritime networks, however, has to do with their start and end points. After all, they could have taken any number of routes in between. To shed light on this gap, an archaeologist decided to follow in the Vikings' footsteps—or, more accurately, their wake.
In order to reconstruct their seafaring itineraries, Lund University archaeologist Greer Jarrett sailed functional Viking-like boats along the Norwegian coast in a series of experimental voyages. By experiencing these journeys firsthand, the archaeologist hoped to understand where it would have made most sense for Viking sailors to seek shelter along the way to their destination. In this way, he identified four natural harbors that could have served as pitstops hundreds of years ago.
'A lot of the time, we only know about the starting and ending points of the trade that took place during the Viking Age. Major ports, such as Bergen and Trondheim in Norway, Ribe in Denmark, and Dublin in Ireland. The thing I am interested in is what happened on the journeys between these major trading centres,' Jarrett explained in a statement. 'My hypothesis is that this decentralised network of ports, located on small islands and peninsulas, was central to making trade efficient during the Viking Age.'
Between September 2021 and July 2022, Jarrett and his crew undertook 15 sailing trials and two approximately three-week-long trial voyages in seven different Nordic clinker boats: traditional, small, open, wooden sailboats whose use in Nordic regions dates back almost 2,000 years. It wasn't always smooth sailing—once, the pole supporting the mainsail snapped over 15 miles (25 kilometers) from the coast, and they had to tie two oars together to secure the sail until they managed to return to land. Overall, they covered 1,494 nautical miles.
The experimental archaeologist decided that possible 'havens' along maritime itineraries should have provided fresh water, shelter from swells and winds, and a good view of the sea. Furthermore, they had to be reachable in low visibility, big enough to host several boats, approachable and exitable from different directions, and located in a 'transition zone': coastal points between exposed regions and inner areas.
Along with these criteria, Jarrett's investigation integrated a digital reconstruction of Viking Age sea levels, pre-established knowledge of large Viking maritime centers, and information about traditional 19th and early 20th century sailboat routes from sailors and fishermen. The archaeologist also clarified that his work regards long-range Viking expeditions rather than voyages for raiding and war purposes.
'This study's emphasis on practical seafaring knowledge and experience seeks to counter the common academic bias towards terrestrial and textual sources and worldviews,' he wrote in the study, published earlier this month in the Journal of Archaeological Method and Theory.
In this way he claims to have identified four potential Viking havens. These remote locations along the Norwegian coast each have varying degrees of pre-existing archaeological evidence indicating past human presence. Presumably, Jarrett is the first to suggest they may have also been pit stops along Viking maritime journeys.
'The list of possible Viking Age havens,' he explained, indicating a diagram in the study, 'is intended as a working document, which can shape and be shaped by future archaeological surveys and excavations.'
It's worth remembering that, even with digital reconstructions of the Viking-era seascape, experimental voyages can never provide evidence of Viking activity to the degree of direct archaeological evidence. Nevertheless, creative and practical approaches such as Jarrett's stand as a reminder that sometimes the solution to a problem requires a different perspective—literally. It remains to be seen whether his work will inspire future archaeological surveys.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI analysis of ancient handwriting gives new age estimates for Dead Sea Scrolls
AI analysis of ancient handwriting gives new age estimates for Dead Sea Scrolls

CNN

time4 hours ago

  • CNN

AI analysis of ancient handwriting gives new age estimates for Dead Sea Scrolls

Many of the Dead Sea Scrolls, some of the most widely known archaeological finds of all time, may be older than once thought, according to a new study. The fresh analysis, which paired radiocarbon dating with artificial intelligence, determined some of the biblical manuscripts date to about 2,300 years ago, when their presumed authors lived, said Mladen Popović, lead author of the report published Wednesday in the journal PLOS One. Bedouin shepherds first spotted the scrolls by chance in the Judaean Desert, near the Dead Sea, in 1947. Archaeologists then recovered thousands of fragments belonging to hundreds of manuscripts from 11 caves, all near the site of Khirbat Qumran in what is now the West Bank. 'The Dead Sea Scrolls were extremely important when they were discovered, because they completely changed the way we think about ancient Judaism and early Christianity,' said Popović, who is also dean of the Faculty of Religion, Culture and Society at the University of Groningen in the Netherlands. 'Out of around 1,000 manuscripts, a bit more than 200 are what we call biblical Old Testament, and they are the oldest copies we have of the Hebrew Bible. They gave us a lot of information about what the text looked like back then.' The scrolls are like a time machine, according to Popović, because they let scholars see what people were reading, writing and thinking at the time. 'They are physical, tangible evidence of a period of history that is crucial — whether you're Christian, Jewish or don't believe at all, because the Bible is one of the most influential books in the history of the world, so the scrolls allow us to study it as a form of cultural evolution,' he said. Almost none of the Dead Sea Scrolls — which were written mostly in Hebrew on parchment and papyrus — have dates on them. Based primarily on paleography, the study and deciphering of ancient writing and manuscripts, scholars have believed the manuscripts range from the third century BC to the second century AD. 'But now, with our project, we have to date some manuscripts already to the end of the fourth century BCE,' he said, meaning that the earliest scrolls could be up to 100 years older than previously thought. 'That's really exciting because it opens up new possibilities to think about how these texts were written and how they moved to other users and readers — outside of their original authors and their social circles,' Popović added. The findings will not only inspire further studies and affect historical reconstructions, according to the authors of the report, but will also unlock new prospects in the analysis of historical manuscripts. Earlier estimates of the manuscripts' age came from radiocarbon dating conducted in the 1990s. Chemist Willard Libby developed this method — used to ascertain the age of organic materials — in the late 1940s at the University of Chicago. Also known as carbon 14 dating, a chemical analysis of a sample, such as a fossil or manuscript, determines the quantity of carbon 14 atoms it contains. All living organisms absorb this element, but it starts to decay as soon as death occurs, so looking at how much is left can give a fairly accurate age of an organic specimen as old as about 60,000 years. Carbon dating has downsides, however. The analyzed sample is destroyed during the process, and some results can be misleading. 'The problem with earlier tests (on the scrolls) is that they didn't address the issue of castor oil,' Popović said. 'Castor oil is a modern invention, and it was used in the 1950s by the original scholars to make the text more legible. But it's a modern contaminant, and it skews the radiocarbon result to a much more modern date.' The study team first used new radiocarbon dating, applying more modern techniques, on 30 manuscripts, which revealed that most of them were older than previously thought. Only two were younger. The researchers then used high-resolution images of these newly dated documents to train an AI they developed, called Enoch after the Biblical figure who was the father of Methuselah. The scientists presented Enoch with more documents they had carbon-dated, but withheld the dating information, and the AI correctly guessed the age 85% of the time, according to Popović. 'In a number of cases, the AI even gave a narrower date range for the manuscripts than the carbon 14 did,' he said. Next, Popović and his colleagues fed Enoch more images from 135 different Dead Sea Scrolls that were not carbon-dated and asked the AI to estimate their age. The scientists rated the results as 'realistic' or 'unrealistic,' based on their own paleographic experience, and found that Enoch had given realistic results on 79% of the samples. Some of the manuscripts in the study were found to be 50 to 100 years older than formerly thought, Popović said. One sample from a scroll known to contain verse from the Book of Daniel was once believed to date to the second century BC. 'That was a generation after the original author,' Popović said, 'and now with the carbon 14, we securely move it (further back) to the time of the author.' Another manuscript, with verses from the Book of Ecclesiastes, also dates older, Popović added. 'The manuscript was previously dated on paleographic grounds to 175 to 125 BCE, but now Enoch suggests 300 to 240 BCE,' he said. Eventually, artificial intelligence could supplant carbon 14 as a method of dating manuscripts, Popović suggested. 'Carbon 14 is destructive,' he said, 'because you need to cut off a little piece of the Dead Sea Scroll, and then it's gone. It's only 7 milligrams, but it's still stuff that you lose. With Enoch, you don't have to do any of this. This a first step. There are all sorts of possibilities to improve Enoch further.' If the team pushes forward with Enoch's development, Popović believes it could be used to assess scripts such as Syriac, Arabic, Greek and Latin. Scholars who were not involved with the study were encouraged by the findings. Having both AI and an enhanced carbon 14 dating method allows a level of calibration across both methodologies that is helpful, according to Charlotte Hempel, a professor of Hebrew Bible and Second Temple Judaism at the University of Birmingham in the United Kingdom. 'The pronounced pattern seems to be that AI offers a narrower window within the Carbon 14 window,' she said via email. 'I wonder whether this suggests a higher level of precision, which would be extremely exciting.' The study represents a first attempt to harness AI technology to extend existing scientific knowledge from carbon 14 dating of certain manuscripts to other manuscripts, said Lawrence H. Schiffman, Global Distinguished Professor of Hebrew and Judaic Studies at New York University. 'To some extent, it is not yet clear whether or not the new method will provide us with reliable information on texts that have not yet been Carbon-14 dated,' he added via email. 'The interesting comments regarding revision of the dating of some manuscripts that may be expected through further development of this approach or new carbon-14 dating, while not new to this study, constitute a very important observation about the field of Dead Sea Scrolls in general.' Commenting on the computational aspects of the study, Brent Seales, the Alumni Professor of Computer Science at the University of Kentucky, said the approach taken by the authors seems rigorous even if the sample sizes are small. Using AI to completely replace carbon dating may be premature, however. '(AI) is a useful tool to incorporate into the broader picture, and to make estimates in the absence of Carbon-14 based on the witness of other similar fragments,' Seales wrote in an email. 'Like everything with machine learning, and like a fine wine, it should get better over time and with more samples. The dating of ancient manuscripts is an extremely difficult problem, with sparse data and heavy constraints on access and expertise. Bravo to the team for this data-driven contribution that takes a massive step forward.'

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma
Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

Yahoo

timea day ago

  • Yahoo

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

OSLO, Norway, June 6, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug Designation (ODD) for GLIX1, the company's lead molecule, for the treatment of glioma, one of the most devastating and lethal brain cancers. Significant clinical benefit beyond current therapies. The designation marks a major regulatory milestone for Hemispherian, recognizing both the urgent unmet medical need in glioma and the potential of GLIX1 to offer significant clinical benefit beyond current therapies. "We are proud to have received this recommendation for an Orphan Drug Designation from the EMA Committee. This validates our scientific approach and supports our mission to transform treatment for patients with glioma, who currently face extremely limited and ineffective options," said Zeno Albisser, CEO of Hemispherian. About the Designation Following a detailed review, the COMP determined that GLIX1 meets the criteria for orphan designation under Regulation (EC) No 141/2000. In particular: Glioma is a life-threatening and chronically debilitating disease affecting approximately 2.6 in 10,000 people in the EU. Existing therapies for Glioblastoma (a form of Glioma) offer only limited survival benefits, with median overall survival typically less than 15 months. Non-clinical studies with GLIX1 demonstrated significant tumor reduction and extended survival in validated animal models, including cases of complete tumor eradication. These results suggest that GLIX1 offers a clinically relevant advantage over existing treatments, fulfilling the EMA's criteria for "significant benefit." Benefits of Orphan Drug Designation- Faster market Access- 10 Years of market Exclusivity Orphan Drug Designation by the EMA provides Hemispherian with a range of development and commercial incentives, including: 10 years of market exclusivity in the EU upon approval. Protocol assistance and regulatory guidance from EMA during clinical development. Eligibility for fee reductions for regulatory submissions, including marketing authorization. These incentives are designed to encourage the development of innovative treatments for rare diseases with high unmet need. About Hemispherian Hemispherian is an Oslo-based pharmaceutical company focused on the development of a novel class of small-molecule drugs targeting glioblastoma and other aggressive cancers. The company's proprietary GLIX platform is based on unique DNA-targeting technology aimed at improving patient survival and quality of life. So far, the treatment shows impressive effects, with limited to no side effects, and with no damage to healthy tissue. Contact: Zeno Albisser, CEO – zeno@ +47 40603455 View original content: SOURCE Hemispherian AS Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma
Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

Yahoo

timea day ago

  • Yahoo

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

OSLO, Norway, June 6, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug Designation (ODD) for GLIX1, the company's lead molecule, for the treatment of glioma, one of the most devastating and lethal brain cancers. Significant clinical benefit beyond current therapies. The designation marks a major regulatory milestone for Hemispherian, recognizing both the urgent unmet medical need in glioma and the potential of GLIX1 to offer significant clinical benefit beyond current therapies. "We are proud to have received this recommendation for an Orphan Drug Designation from the EMA Committee. This validates our scientific approach and supports our mission to transform treatment for patients with glioma, who currently face extremely limited and ineffective options," said Zeno Albisser, CEO of Hemispherian. About the Designation Following a detailed review, the COMP determined that GLIX1 meets the criteria for orphan designation under Regulation (EC) No 141/2000. In particular: Glioma is a life-threatening and chronically debilitating disease affecting approximately 2.6 in 10,000 people in the EU. Existing therapies for Glioblastoma (a form of Glioma) offer only limited survival benefits, with median overall survival typically less than 15 months. Non-clinical studies with GLIX1 demonstrated significant tumor reduction and extended survival in validated animal models, including cases of complete tumor eradication. These results suggest that GLIX1 offers a clinically relevant advantage over existing treatments, fulfilling the EMA's criteria for "significant benefit." Benefits of Orphan Drug Designation- Faster market Access- 10 Years of market Exclusivity Orphan Drug Designation by the EMA provides Hemispherian with a range of development and commercial incentives, including: 10 years of market exclusivity in the EU upon approval. Protocol assistance and regulatory guidance from EMA during clinical development. Eligibility for fee reductions for regulatory submissions, including marketing authorization. These incentives are designed to encourage the development of innovative treatments for rare diseases with high unmet need. About Hemispherian Hemispherian is an Oslo-based pharmaceutical company focused on the development of a novel class of small-molecule drugs targeting glioblastoma and other aggressive cancers. The company's proprietary GLIX platform is based on unique DNA-targeting technology aimed at improving patient survival and quality of life. So far, the treatment shows impressive effects, with limited to no side effects, and with no damage to healthy tissue. Contact: Zeno Albisser, CEO – zeno@ +47 40603455 View original content: SOURCE Hemispherian AS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store